Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Weekly Oral GS-1720 and GS-4182 for Untreated HIV-1 Patients

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of HIV-1 infection, a virus that attacks the immune system and can lead to acquired immunodeficiency syndrome (AIDS) if not treated. The study will compare the effectiveness and safety of a new treatment regimen involving two investigational drugs, GS-1720 and GS-4182, taken together once a week, against an existing medication called Biktarvy. Biktarvy is a combination of three active substances: emtricitabine, tenofovir alafenamide, and bictegravir, which is already used to treat HIV-1.

The purpose of the study is to evaluate how well the new weekly treatment works compared to Biktarvy in people who have not received any prior treatment for their HIV-1 infection. Participants in the study will be randomly assigned to receive either the new weekly treatment or Biktarvy. The study will last for up to 48 weeks, during which participants will have regular check-ups to monitor their health and the effectiveness of the treatment. The study aims to see if the new treatment can maintain low levels of the virus in the blood, similar to Biktarvy.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The study will also collect information on how the new treatment affects the immune system and the levels of the virus in the blood over time. This research is important for developing new treatment options for people living with HIV-1, potentially offering a more convenient weekly dosing schedule compared to daily medication.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying that the participant is 18 years or older, able to provide informed consent, and has not received antiretroviral treatment, except for specific pre-exposure or post-exposure prophylaxis.

    The participant's HIV-1 RNA levels are measured to ensure they are 500 copies/mL or higher.

  2. Step 2

    Randomization and treatment assignment

    Participants are randomly assigned to one of two treatment groups. One group receives a weekly oral regimen of GS-1720 in combination with GS-4182, while the other group receives Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) daily.

    The medications are administered orally in tablet form.

  3. Step 3

    Treatment phase 2

    During Phase 2, the efficacy of the treatments is evaluated over 24 weeks. The primary goal is to determine the proportion of participants with HIV-1 RNA levels below 50 copies/mL at Week 24.

    Participants attend regular check-ups to monitor their health and the effectiveness of the treatment.

  4. Step 4

    Treatment phase 3

    In Phase 3, the study continues for an additional 24 weeks, totaling 48 weeks. The primary goal is to evaluate the proportion of participants with HIV-1 RNA levels below 50 copies/mL at Week 48.

    Secondary assessments include changes in HIV-1 RNA levels and CD4 cell counts, as well as monitoring for any adverse effects.

  5. Step 5

    Extended monitoring

    For some participants, the study may extend to 96 weeks to further assess the long-term efficacy and safety of the treatments.

    Regular monitoring continues, focusing on maintaining HIV-1 RNA levels below 50 copies/mL and observing any long-term effects.

Who can join the trial?

4 criteria

  • Participants must be **18 years of age or older** and able to understand and give written informed consent.
  • Participants assigned male at birth and participants assigned female at birth and of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified methods of **contraception**. This means using methods to prevent pregnancy as outlined in the study guidelines.
  • Participants must have **HIV-1 RNA** levels of **500 copies/mL or higher** at the time of screening. HIV-1 RNA is a measure of the amount of HIV virus in the blood.
  • Participants must be **antiretroviral (ARV) treatment naive**, which means they have not received treatment for HIV before, except for the use of oral pre-exposure prophylaxis or post-exposure prophylaxis with specific medications (Truvada® or Descovy®) up to 1 month before screening. These medications are used to prevent HIV infection.

Who cannot join the trial?

7 criteria

  • Individuals who are not diagnosed with HIV-1 Infection cannot participate. HIV-1 Infection is a type of virus that affects the immune system.
  • Participants who have previously received treatment for HIV-1 Infection are not eligible. This means if you have taken medication for this condition before, you cannot join the study.
  • People who are not within the specified age range for the study cannot participate. The study is looking for individuals in certain age groups.
  • Individuals who are not willing or able to follow the study procedures and requirements cannot join. This means you need to be able to attend appointments and take the study medication as directed.
  • Women who are pregnant or breastfeeding are not eligible to participate. This is to ensure the safety of both the mother and the baby.
  • Participants with certain other medical conditions that might interfere with the study results are not allowed to join. This is to make sure the study results are accurate and reliable.
  • Individuals who are part of another clinical trial cannot participate. This is to avoid any interference with the study results.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • GS-1720

    is an experimental medication being tested for its effectiveness in treating people with HIV-1. It is taken orally once a week and is being studied in combination with another medication, GS-4182, to see how well it works in people who have not received treatment for HIV-1 before.

  • GS-4182

    is another experimental medication used in combination with GS-1720. It is part of a weekly oral treatment regimen being tested for its ability to help control HIV-1 in people who are new to treatment.

  • Biktarvy

    is a medication already approved for the treatment of HIV-1. It combines three active ingredients: bictegravir, emtricitabine, and tenofovir alafenamide. It is used as a comparison in the study to evaluate the effectiveness of the new treatment regimen involving GS-1720 and GS-4182.

What is already known about the treatment

  • GS-1720

    This medication is administered orally as part of a weekly regimen. It is currently being studied in clinical trials for its effectiveness in treating HIV-1 infection, particularly in individuals who have not previously received treatment. The main therapeutic indication is to manage and reduce the viral load in people with HIV-1. At the molecular level, GS-1720 works by inhibiting the replication of the virus, though specific details of its mechanism are still under investigation. It is classified pharmacologically as an antiretroviral agent.

  • GS-4182

    This medication is also taken orally and is part of the same weekly regimen as GS-1720. It is under clinical investigation for its role in treating HIV-1 infection in treatment-naive individuals. The primary therapeutic goal is to control the virus and improve immune function. GS-4182 functions by targeting specific viral components to prevent the virus from multiplying. It belongs to the class of antiretroviral drugs.

  • Biktarvy

    This medication is an oral tablet taken daily and is already approved for use in treating HIV-1 infection. It is a combination of three active ingredients: bictegravir, emtricitabine, and tenofovir alafenamide. Biktarvy is used to reduce the viral load in the body and improve immune system function. It works by blocking the virus's ability to replicate. Biktarvy is classified as an antiretroviral medication.

Investigated diseases

HIV-1 Infection – HIV-1 infection is caused by the human immunodeficiency virus type 1, which attacks the body's immune system, specifically the CD4 cells (T cells). Over time, HIV-1 can destroy so many of these cells that the body can't fight off infections and disease. The virus is transmitted through contact with certain body fluids of an infected person, most commonly during unprotected sex or through sharing needles. Initially, individuals may experience flu-like symptoms, but as the infection progresses, it can lead to more severe immune system damage. Without intervention, HIV-1 can advance to acquired immunodeficiency syndrome (AIDS), where the immune system is severely compromised. The progression of the disease varies among individuals, and it can remain in a latent stage for many years.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IVTrial ID2024-512505-66-00Protocol codeGS-US-695-7156Estimated enrolment675 patientsSponsorGilead Sciences Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.